EVOLENT HEALTH Reports Earnings Results for FY2022 Q4 Ending February 22, 2023.

Earnings Overview

EVOLENT HEALTH ($NYSE:EVH) announced their FY2022 Q4 earnings results on December 31 2022, which were for the quarter ending February 22 2023. Their total revenue decreased by 100.9% year over year, amounting to USD -11.3 million. On a positive note, they saw a 54.0% year-over-year increase in net income, reaching USD 382.4 million.

Transcripts Simplified

In Q4 of 2022, Evolent Health reported over $200 million in new Performance Suite revenue, $58 million from its surgical management offering, and 75% year-over-year revenue growth. The company also benefited from strong cost discipline, with a $4 million improvement in Q4 EHS segment results. Clinical Solutions segment adjusted EBITDA totaled $26.7 million, a modest decline compared to the prior year. The company ended the quarter with 3.3 million lives on the performance suite and an average PMPM fee of $25.78 versus $32.33 a year ago.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Evolent Health. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Evolent Health. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Evolent Health. More…

Key Ratios Snapshot

Some of the financial key ratios for Evolent Health are shown below. More…

Price History

On Wednesday, EVOLENT HEALTH reported its financial results for the fourth quarter of fiscal year 2022, which ended on February 22, 2023. The company’s stock opened at $32.1 on the day and closed at $31.6, down 1.3% from its last closing price of $32.0. Overall, EVOLENT HEALTH had a successful fourth quarter and full year performance despite the challenging environment caused by the pandemic. The company’s strong financial results and robust balance sheet position indicate that it is well-positioned to take advantage of upcoming opportunities in the healthcare market. Live Quote…

Analysis

At GoodWhale, we have conducted an analysis of EVOLENT HEALTH‘s financials. Our Star Chart shows that EVOLENT HEALTH has a low health score of 2/10, indicating that it is less likely to pay off debt and fund future operations. EVOLENT HEALTH is classified as ‘cheetah’, meaning that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given this analysis, investors who are interested in EVOLENT HEALTH should keep in mind that the company is strong in growth, but weak in asset, dividend, and profitability. The company may be attractive to investors who prioritize fast-growth over stability and long-term returns, as it may offer the potential for significant returns in the short term. However, investors should also be aware of the risks associated with this type of investment, such as volatility and potential losses if the company cannot deliver on its growth potential. More…

Peers

The company’s products and services enable healthcare providers to receive and process payments from patients and third-party payers. Evolent Health Inc’s competitors include PreAxia Health Care Payment Systems Inc, Livecare Inc, PT Bundamedik Tbk, and other healthcare payment processing companies.

– PreAxia Health Care Payment Systems Inc ($OTCPK:PAXH)

PreAxia Health Care Payment Systems Inc is a healthcare technology company that provides solutions to healthcare organizations and payers. Its products and services include claims processing, payment processing, and data management. The company was founded in 1997 and is headquartered in Boston, Massachusetts.

– Livecare Inc ($OTCPK:LVCE)

The companyPT Bundamedik Tbk is a leading healthcare provider in Indonesia. The company has a market cap of 4.73T as of 2022 and a ROE of 10.69%. The company is focused on providing quality healthcare services to the Indonesian people. The company has a strong presence in the Indonesian healthcare market and is committed to providing the best possible care to its patients.

Summary

Investors should take note of Evolent Health‘s FY2022 Q4 results, which showed a sharp decline in revenue, falling from USD 11.3 million to USD -11.3 million year-over-year. Despite this drastic drop, the company’s net income surged by 54.0% to USD 382.4 million. Evolent Health appears to have successfully managed their expenses and increased profitability despite decreased revenue, making them a potentially attractive investment opportunity. Further analysis of their financial statements and company trends should be conducted in order to assess the potential for future success.